Senate Rejects Tighter DTC Drug Ad Limits

Share this content:
The U.S. Senate yesterday voted against a proposal that would toughen limits on direct-to-consumer drug ads by requiring advertisers to give equal time to information about side effects and similar drugs.

In a 69-26 vote, the Senate rejected the DTC ad rule changes submitted by Sen. John Edwards, D-NC, as an amendment to the Medicare prescription drug benefit plan currently being considered by Congress.

The new rules would have required DTC drug advertisers to display information about side effects as prominently as they display a drug's benefits. Also, advertisers would have to give equal prominence to information about a drug's effectiveness compared with similar drugs.

The rules would have applied to aural, print and video information in DTC drug ads. In addition, the Food and Drug Administration would have been required to accelerate its reviews of the legality of DTC ads placed by drug companies.


Next Article in Marketing Strategy

Sign up to our newsletters

Company of the Week

Brightcove is the world's leading video platform. The most innovative and respected brands confidently rely on Brightcove to solve their most demanding communication challenges because of the unmatched performance and flexibility of our platform, our global scale and reliability, and our award-winning service. With thousands of customers and an industry-leading suite of cloud video products, Brightcove enables customers to drive compelling business results.

Find out more here »

Career Center

Check out hundreds of exciting professional opportunities available on DMN's Career Center.  
Explore careers in digital marketing, sales, eCommerce, marketing communications, IT, data strategies, and much more. And don't forget to update your resume so employers can contact you privately about job opportunities.

>>Click Here

Relive the 2017 Marketing Hall of Femme

Click the image above